依折麦布治疗特发性肺纤维化的重定位研究
本研究通过人及小鼠肺成纤维细胞体外实验、博来霉素诱导肺纤维化小鼠模型及三家医院患者回顾性分析,探讨依折麦布对特发性肺纤维化的治疗潜力。结果显示依折麦布通过恢复mTORC1-自噬轴抑制肌成纤维细胞分化,并减轻小鼠肺纤维化;规律使用依折麦布的特发性肺纤维化患者全因死亡率和肺功能下降率降低。
要点
- 依折麦布通过恢复mTORC1-自噬轴抑制肌成纤维细胞分化。
- 依折麦布减轻博来霉素诱导的小鼠肺纤维化并增加自噬流。
- 规律使用依折麦布的特发性肺纤维化患者全因死亡率和肺功能下降率降低。
核心结论
- 依折麦布可能是特发性肺纤维化的潜在新型治疗药物。
研究设计与样本
- 采用人及小鼠原代肺成纤维细胞进行体外机制实验。
- 对人肺成纤维细胞行mRNA测序和基因集富集分析。
- 使用博来霉素诱导的肺纤维化小鼠模型评估体内疗效。
- 使用串联荧光标记LC3转基因小鼠测量自噬流。
- 回顾性分析三家医院特发性肺纤维化患者的医疗记录,评估生存和肺功能。
主要发现
- 依折麦布通过精细调控细胞内胆固醇分布恢复mTORC1-自噬轴,抑制肌成纤维细胞分化。
- 血清反应因子被确定为该过程中的主要下游效应物,可能是自噬底物。
- 依折麦布通过抑制mTORC1活性和增加自噬流改善博来霉素诱导的小鼠肺纤维化。
- 规律使用依折麦布的特发性肺纤维化患者全因死亡率和肺功能下降率降低。
临床怎么用
- 依折麦布作为已获批的降脂药,可能为特发性肺纤维化患者提供新的治疗选择。
- 需进一步临床试验验证依折麦布对特发性肺纤维化的疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We previously identified ezetimibe, an inhibitor of Niemann-Pick C1-like intracellular cholesterol transporter 1 and European Medicines Agency-approved lipid-lowering agent, as a potent autophagy activator. However, its efficacy against pulmonary fibrosis has not yet been evaluated. This study aimed to determine whether ezetimibe has therapeutic potential against idiopathic pulmonary fibrosis. METHODS: Primary lung fibroblasts isolated from both humans and mice were employed for mechanistic in vitro experiments. mRNA sequencing of human lung fibroblasts and gene set enrichment analysis were performed to explore the therapeutic mechanism of ezetimibe. A bleomycin-induced pulmonary fibrosis mouse model was used to examine in vivo efficacy of the drug. Tandem fluorescent-tagged microtubule-associated protein 1 light chain 3 transgenic mice were used to measure autophagic flux. Finally, the medical records of patients with idiopathic pulmonary fibrosis from three different hospitals were reviewed retrospectively, and analyses on survival and lung function were conducted to determine the benefits of ezetimibe. RESULTS: Ezetimibe inhibited myofibroblast differentiation by restoring the mechanistic target of rapamycin complex 1-autophagy axis with fine control of intracellular cholesterol distribution. Serum response factor, a potential autophagic substrate, was identified as a primary downstream effector in this process. Similarly, ezetimibe ameliorated bleomycin-induced pulmonary fibrosis in mice by inhibiting mechanistic target of rapamycin complex 1 activity and increasing autophagic flux, as observed in mouse lung samples. Patients with idiopathic pulmonary fibrosis who regularly used ezetimibe showed decreased rates of all-cause mortality and lung function decline. CONCLUSION: Our study presents ezetimibe as a potential novel therapeutic for idiopathic pulmonary fibrosis.
引用
- Lee C, Kwak SH, Han J, et al. Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2024. PMID: 38359963. doi:10.1183/13993003.00580-2023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。